Startups

Camden Partners Nexus co-leads $3.7M investment in pharmaceutical company treating hearing loss

The funding from the Baltimore-based venture fund and Savoir Capital is part of a Series A round for Spiral Therapeutics, which has an R&D presence at Johns Hopkins.

Inside FastForward 1812, an East Baltimore-based incubator home that is based in East Baltimore. (Photo by Stephen Babcock)

Early-stage pharmaceutical company Spiral Therapeutics received $3.7 million in new investment as it looks to advance treatments for hearing loss and other inner ear disorders.
The first close of the Series A round was led by Baltimore-based Camden Partners Nexus and Savoir Capital.
The company’s initial drug candidate, LPT99, moved into the clinical phase of a Phase I study this month. In the fall, the company reported positive feedback from the U.S. Food and Drug Administration in response to an initial submission, which plans to develop the treatment for the prevention of chemotherapy-induced hearing loss in pediatric patients. The company is also exploring further use for other types of hearing loss.
“This round of financing allows us to take LPT99 into the clinic and further validates our development strategy,” said Hugo Peris, founder and CEO of Spiral Therapeutics.
Launched in early 2016, the San Francisco–based company has a research and development presence in Baltimore through a collaboration with Johns Hopkins, as well as in Barcelona, Spain.
“Spiral Therapeutics brings together innovative therapies addressing inner ear disorders and a seasoned and energetic management team,” George Petrocheilos, a general partner at Camden Partners who will join the company’s board, said in a statement. “Its solid R&D foundation and the meaningful collaborations with leading medical institutions like Johns Hopkins and UCSF make Spiral an ideal investment for Camden.”
Camden Partners Nexus, the biomedical-focused venture fund of Inner Harbor–based Camden Partners that focuses on companies commercializing research, recently made investments in local startups including Sisu Global Health and WindMIL Therapeutics, among other deals since making its final close at the end of 2017.

Companies: Camden Partners

Before you go...

Please consider supporting Technical.ly to keep our independent journalism strong. Unlike most business-focused media outlets, we don’t have a paywall. Instead, we count on your personal and organizational support.

Our services Preferred partners The journalism fund
Engagement

Join our growing Slack community

Join 5,000 tech professionals and entrepreneurs in our community Slack today!

Trending

Entrepreneurship is changing, and so is the economic development behind it

Tech Hubs’ new $210M funding leaves Baltimore and Philly off the table

Here’s what to know before using AI to craft your brand’s social media posts

RIP Dan Gincel: Former colleagues remember Maryland biotech leader’s love for life sciences, community and jokes

Technically Media